Clinical trials: Somatostatin Receptor-positive Neuroendocrine Tumor
Neuroendocrine Carcinoma
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers and other imaging modalities like CT…
- Trial name
- NCT01879657
- Testing
- 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Radio Isotope Therapy of America
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
CNS Tumors, Meningioma
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma…
- Conditions
- CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma
- Trial name
- DOMINO-START (NCT04081701)
- Testing
- Ga68-DOTATATE-PET/MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Neuroendocrine Tumors
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
his was a single-center, single-arm phase II study evaluate the efficacy and safety of Lutetium[177Lu] Oxodotreotide Injection in the first-line treatment of unresectable or metastatic, progressive, G2 or G3, somatostatin…
- Trial name
- NCT05894486
- Testing
- Lutetium[177Lu] Oxodotreotide Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Metastatic Neuroendocrine Tumor
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors…
- Trial name
- NCT05724108
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 25 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Post-Authorization Long-Term Safety Study of LUTATHERA
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
- Trial name
- SALUS (NCT03691064)
- Testing
- LUTATHERA
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,014 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy.
- Conditions
- Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
- Trial name
- LEVEL (NCT05918302)
- Testing
- 177Lu-edotreotide, Everolimus
- Where
- 27 sites in Belgium, France and 2 more
- Volunteers
- 170 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Clinical Trial, Phase I, Neuroendocrine Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
- Conditions
- Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
- Trial name
- LuPARP (NCT04375267)
- Testing
- 177Lu-DOTA-TATE + olaparib
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Gastroenteropancreatic Neuroendocrine Tumors
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
- Trial name
- NCT02162446
- Testing
- satoreotide trizoxetan
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Ipsen
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Thyroid Cancer, Prostate Cancer
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
- Conditions
- Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors
- Trial name
- BCB RIV (NCT04104529)
- Testing
- Biological collection, tumor collection
- Where
- 4 sites in France
- Volunteers
- 350 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Adult Medulloblastoma, Childhood Medulloblastoma
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with…
- Conditions
- Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor
- Trial name
- NCT01869725
- Testing
- gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Sue O'Dorisio
Neuroendocrine Tumors
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors.
- Trial name
- NCT04888481
- Testing
- 68Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- University of Alberta
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.
- Trial name
- NCT06122610
- Testing
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Somatostatin Receptor-positive GEP-NET
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world…
- Trial name
- NCT04946305
- Testing
- Lutathera
- Where
- 6 sites in South Korea
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg)…
- Trial name
- NETTER-1 (NCT01578239)
- Testing
- Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 231 people
- Sponsor
- Advanced Accelerator Applications
Gastroenteropancreatic Neuroendocrine Tumor
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed…
- Trial name
- REAL-LU (NCT04727723)
- Testing
- Lutathera®
- Where
- 18 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors.
- Trial name
- NCT04234568
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)